MannKind (MNKD) Expected to Announce Earnings on Wednesday

MannKind (NASDAQ:MNKD) is anticipated to issue its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect MannKind to post earnings of ($0.0575) per share and revenue of $107.74 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:00 AM ET.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). The company had revenue of $109.37 million for the quarter, compared to the consensus estimate of $108.08 million. MannKind’s revenue for the quarter was up 43.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.05 earnings per share. On average, analysts expect MannKind to post ($0.21) EPS for the current fiscal year and $0.01 EPS for the next fiscal year.

MannKind Trading Up 1.9%

Shares of MNKD opened at $3.29 on Wednesday. The firm has a 50-day moving average price of $3.63 and a 200 day moving average price of $3.79. MannKind has a 52-week low of $2.23 and a 52-week high of $6.51.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Wells Fargo & Company decreased their price target on MannKind from $14.00 to $13.00 and set an “overweight” rating for the company in a research note on Thursday, August 6th. HC Wainwright restated a “buy” rating on shares of MannKind in a report on Thursday, July 23rd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of MannKind in a research note on Friday, October 2nd. Chardan Capital initiated coverage on shares of MannKind in a report on Monday, October 19th. They issued a “buy” rating and a $10.00 price target for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $8.00 price objective on shares of MannKind in a research report on Tuesday, October 20th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.08.

Insider Buying and Selling at MannKind

In other news, Director Steven Binder sold 39,051 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $4.06, for a total transaction of $158,547.06. Following the completion of the sale, the director owned 785,867 shares in the company, valued at approximately $3,190,620.02. This represents a 4.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders have sold 111,660 shares of company stock worth $414,881. 2.60% of the stock is currently owned by company insiders.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).